Dai, Lijun, Paul S. Brookes, Victor M. Darley-Usmar, and Peter G. Anderson. Bioenergetics in cardiac hypertrophy: mitochondrial respiration as a pathological target of NO⅐. Am J Physiol Heart Circ Physiol 281: H2261-H2269, 2001.-A rat aortic banding model of cardiac hypertrophy was used to test the hypothesis that reversible inhibition of mitochondrial respiration by nitric oxide (NO⅐) elicits a bioenergetic defect in the hypertrophied heart. In support of this hypothesis, the respiration of myocytes isolated from hypertrophied hearts was more sensitive to exogenous NO⅐ (IC50 200 Ϯ 10 nM vs. 290 Ϯ 30 nM in controls, P ϭ 0.0064). Hypertrophied myocytes also exhibited significantly elevated inducible NO⅐ synthase (iNOS). Consistent with this endogenous source for NO⅐, the respiration of hypertrophied myocytes was significantly inhibited at physiological O2 tensions versus controls. Both the nonspecific NOS inhibitor nitro-Larginine and the iNOS-specific inhibitor N- [3-(aminomethyl)benzyl]acetamidine ⅐ 2HCl reversed this inhibition, with no effect on respiration of control myocytes. Consistent with an NO⅐-mediated mitochondrial dysfunction, the ability of intact perfused hearts to respond to a pacing workload was impaired in hypertrophy, and this effect was reversed by NOS inhibition. We conclude that endogenously generated NO⅐ can modulate mitochondrial function in the hypertrophied heart and suggest that this bioenergetic defect may underlie certain pathological features of hypertrophy. heart failure; cardiomyocytes; iNOS; oxidative phosphorylation CARDIAC HYPERTROPHY is a complex pathological process, contributing to the development of congestive heart failure (19, 23). It is reported that cardiac hypertrophy results in a modified cardiac metabolism including elevated glycolysis and lactate production (1-3), overexpression of fetal isozymes (48), and impaired ATP regeneration and functional recovery after ischemiareperfusion (4, 22, 34, 38) . These metabolic changes are consistent with a defect at the mitochondrial level (22, 24, 47) , and several studies have reported dysfunctional mitochondria in hypertrophy (5, 37, 41). Paradoxically, it has also been reported that mitochondria isolated from the hypertrophied heart are normal regarding maximal activities necessary for oxidative phosphorylation (8, 14, 27) . In support of the hypothesis that a mitochondrial dysfunction may contribute to the pathology of cardiac hypertrophy, several heritable mitochondrial DNA mutations result in a hypertrophic cardiomyopathy phenotype (42-44).
heart failure; cardiomyocytes; iNOS; oxidative phosphorylation CARDIAC HYPERTROPHY is a complex pathological process, contributing to the development of congestive heart failure (19, 23) . It is reported that cardiac hypertrophy results in a modified cardiac metabolism including elevated glycolysis and lactate production (1-3), overexpression of fetal isozymes (48) , and impaired ATP regeneration and functional recovery after ischemiareperfusion (4, 22, 34, 38) . These metabolic changes are consistent with a defect at the mitochondrial level (22, 24, 47) , and several studies have reported dysfunctional mitochondria in hypertrophy (5, 37, 41) . Paradoxically, it has also been reported that mitochondria isolated from the hypertrophied heart are normal regarding maximal activities necessary for oxidative phosphorylation (8, 14, 27) . In support of the hypothesis that a mitochondrial dysfunction may contribute to the pathology of cardiac hypertrophy, several heritable mitochondrial DNA mutations result in a hypertrophic cardiomyopathy phenotype (42) (43) (44) .
In a recent study (8) , we hypothesized that the reversible inhibition of mitochondrial cytochrome-c oxidase (complex IV) by nitric oxide (NO⅐) might account for this apparent paradox between in vitro and in vivo findings. It was found that mitochondria isolated from hypertrophied hearts exhibited an increased sensitivity to inhibition of cytochrome-c oxidase by NO⅐. Investigating this in a cellular or organ setting is complex because NO⅐ has multiple effects both in normal cardiac function and in disease. For example, NO⅐ produced by the constitutive endothelial form of NO⅐ synthase (eNOS) can modulate cardiomyocyte energetics (28, 50) , contractility, blood flow, and platelet aggregation (17) . In contrast, high levels of NO⅐ from inducible NO⅐ synthase (iNOS) are associated with several diseases including cardiac allograft rejection, dilated cardiomyopathy, and congestive heart failure (16, 21, 31, 33, 46) . Little is known of the factors that establish responses to NO⅐ as protective or pathological. These may include the sensitivity of mitochondrial respiration to NO⅐ and the bioavailability of NO⅐ controlled by its reactions with other species such as superoxide.
To further understand the role of NO⅐ and mitochondrial dysfunction in cardiac hypertrophy, this study directly addresses the question of whether the increased sensitivity to NO⅐ revealed in isolated mitochondria from hypertrophied hearts (8) is present in both the cellular and whole organ milieu. To avoid confounding effects of NO⅐ on factors such as platelet aggregation and neutrophil recruitment, these experiments were performed in isolated cardiomyocytes and in buffer-perfused hearts. Herein it is reported that hypertrophied cardiomyocytes exhibit a greater sensitivity of respiration to NO⅐ inhibition. It is also shown that iNOS protein and activity are upregulated in hypertrophy and that NO⅐ from this iNOS can inhibit respiration at physiological O 2 tensions. Finally, it is reported that impaired contractile function in hyper-trophy, specifically the ability to respond to a pacing workload, is restored by NOS inhibition. The implications for these findings are discussed in the context of the control of respiration in response to stress in the hypertrophied heart.
MATERIALS AND METHODS

Animals and supplies.
Male Sprague-Dawley rats were from Harlan (Indianapolis, IN); NO⅐ synthase (NOS) inhibitors nitro-L-arginine and N- [3-(aminomethyl) benzyl]acetamidine ⅐ 2HCl (1400W) were from Aldrich (Milwaukee, WI); and 1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA NONOate) was from Alexis (San Diego, CA). Type II collagenase was from Worthington (Freehold, NJ). Antibodies to iNOS and eNOS were from BD Bioscience (San Diego, CA). L- [2,3- 3 H]arginine was from New England Nuclear (Boston, MA). Enhanced chemiluminescence (ECL) reagents were from Amersham-Pharmacia (Piscataway, NJ). ATP assay reagents were from Promega (Madison, WI). All other biochemicals and reagents, analytical grade or higher, were from Sigma (St. Louis, MO). Stock solutions of DETA NONOate were prepared in 10 mM NaOH and stored at Ϫ20°C. Their decomposition, assayed spectrophotometrically at 251 nm, was not significant during 1 wk.
Animal model of cardiac hypertrophy. Animals were housed with food and water available ad libitum, according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, 1996) . Cardiac hypertrophy was elicited by aortic banding as previously described (1, 3) . Briefly, after anesthesia with methohexital sodium (0.5 mg/ 100 g ip), a 0.6-mm band was placed around the ascending aorta of 23-day-old rats (ϳ50 g body mass). Control animals underwent identical surgery without placement of the band. Aortic-banded (Band) and control (Sham) animals were studied at 8-12 wk postsurgery. In agreement with previous studies (1, 3, 8) , the heart weight-to-body weight ratio was increased 46.6 Ϯ 6.3%, and there was no evidence of fibrosis. This degree of hypertrophy has previously been shown not to elicit impaired contractile function (1, 3) . In this particular model of hypertrophy, congestive heart failure typically develops around 20-24 wk postsurgery.
Cardiomyocyte isolation. Calcium-tolerant ventricular myocytes were isolated from the hearts of 8-to 12-wk postsurgery rats (250-350 g) by collagenase perfusion according to Powell (35) with minor modifications. After pentobarbital anesthesia (50 mg/kg ip), hearts were rapidly extirpated and perfused with 37°C oxygenated (95% O 2-5% CO2) KrebsHenseleit (KH) buffer, composed of (in mM) 118 NaCl, 2.6 KCl, 14.5 NaHCO3, 1.2 MgSO4, 11 glucose, and 1.2 KH2PO4. Perfusion was at 12 ml ⅐ min Ϫ1 ⅐ g wet wt Ϫ1 for 5 min. All other buffers were based on modified KH with 50 M Ca 2ϩ (KHCa 2ϩ ). The nominally Ca 2ϩ -free perfusion was followed by 6 min/g perfusion at 6 ml ⅐ min Ϫ1 ⅐ g Ϫ1 with KHCa 2ϩ plus fat-free BSA (0.1% wt/vol), taurine (10 mM), and type II collagenase (140 U/ml). Ventricular tissue was then removed, chopped, and incubated for 4 min/g at 37°C in an aerated conical flask in 10 ml/g of fresh collagenase buffer plus fat-free BSA (2% wt/vol). Tissue was disaggregated by pipetting and then filtered through 300-m nylon mesh, and 10-20 ml of KHCa 2ϩ plus BSA (2% wt/vol) was added. Cells were centrifuged at 30 g for 1 min. The cell pellet was resuspended in 10 ml of KHCa 2ϩ , layered onto 30 ml of KHCa 2ϩ plus BSA (4% wt/vol), and centrifuged again. The layering/centrifugation step was repeated, and the cell pellet was finally resuspended in KH with 1 mM CaCl2 plus BSA (2% wt/vol). Cell count was adjusted to 10 6 cells/ml, and the suspension was kept for up to 1.5 h at room temperature with 95% O 2-5% CO2 blowing over the surface and gentle agitation. This protocol yielded 4-6 ϫ 10 6 cells/heart with 70-80% of cells being rod shaped and excluding Trypan blue. Consistent with a hypertrophic response at the individual cell level, the protein content of Band cells was significantly higher than that of Sham cells (22.3 Ϯ 2.0 vs. 17.0 Ϯ 0.9 mg protein/10 6 cells, respectively; P ϭ 0.028). Protein concentration of cell suspensions was determined using Folin-phenol reagent against a standard curve constructed using BSA (29) .
Detection of NOS protein by Western blot. Within 1 h of isolation, myocytes (10 6 cells) were pelleted and resuspended in 0.5 ml of ice-cold lysis buffer composed of 10 mM Tris, 1% SDS, 1 g/ml aprotinin, 1 g/ml leupeptin, 10 g/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM Na 2VO3, 1 mM EDTA, and 1 mM benzamidine, pH 7.4. Lysates were sonicated, incubated on ice for 20 min, and then centrifuged at 14,000 g for 20 min. Supernatants were boiled in denaturing sample buffer and electrophoresed on 7.5% polyacrylamide SDS gels (100 g protein/well) followed by transfer to nitrocellulose. Membranes were blocked with Tris-buffered saline plus 0.05% Tween 20 (TBST) containing 10% nonfat dry milk and then probed using rabbit polyclonal antibodies against iNOS or eNOS, dissolved in TBST-5% milk. A peroxidase-linked goat anti-rabbit IgG secondary antibody was used, and detection was by ECL. Densitometry was performed on developed blots using public domain Scion software (National Institutes of Health). Saturation of the ECL signal was determined by analyzing cross-sectional band density plots, and only blots with no saturated bands were used for quantitative analyses. These methods gave a linear response over a Ϸ20-fold range of protein concentrations for appropriate positive controls provided by the antibody manufacturer.
Measurement of enzyme activities. NOS activity was measured by the conversion of [ 3 H]arginine to [ 3 H]citrulline using a NOS assay kit (Calbiochem, San Diego, CA) according to the manufacturer's instructions. Myocytes (10 6 cells) were washed with PBS, washed with PBS containing 1 mM EDTA, and then pelleted by centrifugation for 5 min at 1,000 g. The pellet was resuspended in 200 l homogenization buffer composed of 25 mM Tris, 1 mM EDTA, and 1 mM EGTA, pH 7.4, and the cells were disrupted by pipetting and freeze-thawing. Protein content of homogenates was then determined (29) . Homogenate (10 l) was added to 40 l reaction mix containing (final concentrations) 25 mM Tris, 3 M tetrahydrobiopterin, 1 M flavin adenine dinucleotide, 1 M flavine mononucleotide, 1 mM NADPH, and 0.375 M [ 3 H]arginine (specific activity 53.4 Ci/mmol), pH 7.4. After 1 h at 37°C, reactions were stopped by adding 400 l stop buffer composed of 50 mM HEPES and 5 mM EDTA, pH 5.5. Parallel reactions were performed in the presence of either 0.6 mM CaCl2 or 1 mM N G -nitro-L-arginine methyl ester (L-NAME). [ 3 H]citrulline was separated from the reaction mixture by cation-exchange chromatography using equilibrated Dowex 50W-X8 resin and quantified by liquid scintillation counting. Total NOS activity was determined by subtracting L-NAME-blocked counts from counts in the presence of CaCl2. Calcium-independent activity (iNOS activity) was determined by subtracting L-NAME-blocked counts from counts in the absence of CaCl2 (16, 45) .
Measurement of oxygen consumption and NO⅐. Oxygen and NO⅐ were measured simultaneously using appropriate Clarktype electrodes in a 1-ml magnetically stirred 37°C chamber as previously described (8) . The NO⅐ electrode was calibrated using authentic NO⅐ gas at both high (ϳ240 M) and low (ϳ25 M) concentrations of O2. Because the reaction between NO⅐ and O 2 in the buffer is faster at high O2 concentrations, the NO⅐ electrode gives a smaller current response at high O2 for the same amount of added NO⅐. The ratio of the electrode current response at high versus low O 2 was used as a correction factor to determine actual concentrations of NO⅐ from recorded values as recently described (40) . Myocytes were incubated at 10 5 cells/ml in KH plus BSA (2% wt/vol) and Ca 2ϩ (1 mM). Because quiescent myocytes respire slowly, the protonophore FCCP (2 M) was added to initiate uncoupled respiration. Stirring speeds were optimized to avoid mechanical disruption of cells without affecting electrode response. Data were collected with the use of a digital recording device (Dataq, Akron, OH) connected to a personal computer.
Myocytes were incubated as described above in the presence or absence of the NOS inhibitor nitro-L-arginine (1 mM). When the O 2 concentration reached 90% saturation (216 M; assuming 100% ϭ 240 M), DETA NONOate (0.9 mM) was added, resulting in a steady release of NO⅐ and progressive inhibition of myocyte respiration. Oxygen consumption rate and NO⅐ concentration data were taken at several corresponding time points and used to construct graphs showing respiration rate as a function of NO⅐ concentration. Data were expressed as a percentage of the maximal rate in each experiment, i.e., normalized to the initial rate before the addition of NO⅐.
To measure the effects of endogenously produced NO⅐ on respiration, myocytes were also incubated as described, and their respiration was monitored until all O 2 in the chamber had been consumed. Experiments were performed in random order with buffer alone or in the presence of the nonspecific NOS inhibitor nitro-L-arginine (1 mM) or the specific iNOS inhibitor 1400W (400 M) (18) . The low solubility of these NOS inhibitors in buffer precluded experiments in which NOS inhibitors could be added halfway through an incubation period to monitor acute responses. In addition, these compounds exhibit slow onset of inhibition (18) such that their addition during an incubation would not elicit a response within the time course of a typical experiment. For these reasons, NOS inhibitors were predissolved in the incubation buffer at the desired concentrations.
Measurement of ATP. Myocytes were incubated at 10 5 cells/ml as detailed above. After 1 min, 100-l aliquots of suspension were taken, and protein was removed by perchloric acid precipitation. The ATP content of supernatants was assayed using a luciferase assay kit (Enliten reagent, Promega).
Heart perfusion/pacing studies. To examine the effects of endogenously generated NO⅐ on cardiac contractile function, hearts were rapidly extirpated and perfused at 12 ml ⅐ min Ϫ1 ⅐ g wet wt Ϫ1 with KH buffer (see Cardiomyocyte isolation) containing 2.5 mM CaCl 2 bubbled with (95% O2-5% CO 2). Contractile function was monitored with a latex balloon in the left ventricle connected to a pressure transducer, and coronary vascular resistance was measured by using a pressure transducer in-line with the perfusion cannula. Both transducers were connected to a digital recording device (Dataq) and a personal computer. Hearts were electrically stimulated at 300 beats/min. After a 15-min equilibration period, the pacing frequency was increased to 360, 420, and 480 beats/min for 3 min at each pacing point. Hearts were then returned to 300 beats/min, and after a 5-min recovery period, the buffer was changed for one containing 1 mM of nitro-L-arginine. After a 15-min wash-in period to allow NOS inhibition to occur, the pacing regimen was repeated (300 3 360 3 420 3 480 3 300 beats/min). Data were averaged from the final 30 s at each pacing point. Left ventricular (LV) developed pressure was calculated as systolic minus diastolic pressure (in mmHg) and expressed as a percentage of the initial 300 beats/min value under each condition.
Statistics. All data are results from at least four independent experiments. Statistical significance between experimental groups was determined using Student's t-test, with P Ͻ 0.05 taken as the significance limit.
RESULTS
Effects of exogenous NO⅐ on cardiomyocyte respiration. In the first series of experiments, the effect of exogenous NO⅐ on the respiration of myocytes isolated from Sham and Band hearts was investigated. To achieve this, myocytes were incubated in a combined NO⅐ and O 2 electrode chamber, and NO⅐ was added from DETA NONOate. Under these conditions of minimal work load, cardiomyocyte respiration is relatively slow due to a low ATP demand. Therefore, the uncoupler FCCP was added to stimulate mitochondrial respiration close to its maximum level. This treatment allows examination of one aspect of mitochondrial oxidative phosphorylation where the electron transport chain is placed under maximal electron flux. This method of stimulating cardiomyocyte respiration is preferential to either field stimulation or infusion of ADP and substrates by permeabilizing the plasma membrane. For example, field stimulation may interfere with electrodes used to measure NO⅐ and O 2 , and detergents may lead to loss of cytosolic factors controlling respiration such as substrates for endogenous NO⅐ synthesis. A potential drawback of using FCCP is that uncoupling mitochondria may shift the control pattern of oxidative phosphorylation, making respiration more sensitive to respiratory chain inhibitors (15) . However, experiments with isolated heart mitochondria showed that the control by complex IV over respiration was identical in either state 3 respiration or with FCCP in both Band and Sham myocytes (not shown). These data support the use of FCCP because they suggest that the effects of inhibitors such as NO⅐ on uncoupled respiration measured here can be recapitulated into effects on fully coupled, ATP-synthesizing mitochondria.
Results from a typical myocyte incubation are shown in Fig. 1A . Addition of the NO⅐ donor DETA NONOate (indicated by the arrow) resulted in a steady release of NO⅐ and progressive inhibition of respiration rate (the slope of the O 2 trace). NO⅐ inhibitor titration curves (Fig. 1, B and C) were constructed by measuring the respiration rate and NO⅐ concentration at paired time points and plotting the corresponding values against each other. Figure 1B shows that the respiration of Band myocytes is more sensitive to NO⅐ than that of Sham myocytes, i.e., less NO⅐ is required to inhibit respiration in Band myocytes. Because iNOS is upregulated in the hypertrophied heart (8), these experiments were also conducted in the presence of nitro-L-arginine to eliminate any effects due to endogenous NO⅐. Figure  1C shows that NOS inhibition did not affect the response to exogenous NO⅐ in Sham or Band myocytes, suggesting that this phenomenon is a property of the mitochondrial respiratory system. From the data used to construct Fig. 1, B and C, the concentration of NO⅐ that resulted in IC 50 respiration was determined for each curve and was significantly lower in Band versus Sham myocytes, as shown in Fig. 1D .
Because the NO⅐ inhibition of mitochondrial respiration is competitive with O 2 , it is possible that different O 2 tensions may elicit the different response to NO⅐ between Sham and Band. However, the O 2 tension at which the NO⅐ IC 50 occurred was not significantly different in the Sham and Band incubations (124 Ϯ 12 vs. 128 Ϯ 9 M O 2 , respectively), removing this as a possible mechanism.
Another important factor that may contribute to the different responses of Sham and Band myocytes to NO⅐ is their consumption of the NO⅐ itself (40) . However, the rates of NO⅐ evolution from DETA NONOate, measured by the NO⅐ electrode, were the same in Sham and Band incubations (0.21 Ϯ 0.05 vs. 0.18 Ϯ 0.03 M/min, respectively, not significant). In addition, the steadystate plateau concentrations of NO⅐ achieved were similar (1.04 Ϯ 0.12 vs. 1.02 Ϯ 0.11 M in Sham and Band, respectively, not significant). These data indicate that the greater apparent sensitivity of Band myocyte respiration to NO⅐ (Fig. 1) is not due to an increased availability of NO⅐ in these cells.
A third factor that may underlie the increased sensitivity of respiration to NO⅐ in Band myocytes is the initial maximum respiration rate (before NO⅐ addition). When normalized to protein, initial respiration rate was significantly different between Sham and Band myocytes (23.1 Ϯ 2.9 vs. 13.6 Ϯ 1.8 mol ⅐ min Ϫ1 ⅐ mg Ϫ1 protein, respectively, P ϭ 0.014). However, when normalized to cell number, respiration rate was not significantly different between Sham and Band myocytes (33.7 Ϯ 3.4 vs. 28.2 Ϯ 1.9 mol ⅐ min Ϫ1 ⅐ 10% cells Ϫ1 , respectively, P ϭ 0.127). The finding that initial respiration normalized to protein is lower in Band cells is unlikely to contribute to the increased sensitivity to NO⅐, because in isolated mitochondria from Band or Sham hearts, maximal respiration rates are identical (8) . In the intact cell, additional control could derive from either substrate delivery or other contributions to total cell protein that are nonmitochondrial in origin.
NOS protein content of cardiomyocytes. Having demonstrated that exogenously added NO⅐ can modulate cardiomyocyte respiration, we next investigated the content of endogenous NO⅐-generating machinery in cardiomyocytes. Myocyte lysates were prepared and analyzed for their content of iNOS and eNOS protein. Figure 2A shows results of a typical iNOS Western blot, with quantitation of several such blots in Fig. 2B . In agreement with our previous findings in whole heart homogenates (8), iNOS is upregulated in Band versus Sham myocytes, by 56 Ϯ 14%. This result also confirms our previous immunohistochemical data (8) , showing that iNOS in hypertrophy is primarily inside myocytes and not the endothelium. Some eNOS expression was detected in isolated myocyte preparations (Fig. 2C) although this was not different between Sham and Band. In addition, NOS activity results (below) suggest that iNOS accounts for the majority of the NOS activity in myocyte preparations.
NOS activity of cardiomyocytes. To determine whether the iNOS measured by Western blotting (Fig. 2) (Fig.  2) . Total NOS activity (in the presence of Ca 2ϩ ) was also higher in Band versus Sham myocytes (Fig. 2B) , although not significantly. These data suggest the majority of NOS in the myocyte preparation is iNOS.
Effects of endogenous NO⅐ on cardiomyocyte respiration.
Having demonstrated an effect of exogenously added NO⅐ on cardiomyocyte respiration and showing that both iNOS protein and activity are upregulated in Band versus Sham myocytes, it is important to determine whether NO⅐ from this iNOS can inhibit hypertrophied myocyte respiration. The inhibition of respiration by NO⅐ is competitive with O 2 (9) (10) (11) . Thus when cells producing NO⅐ are incubated in a sealed chamber, their respiration rate gradually decelerates with time, as they utilize the finite amount of O 2 in the chamber. This has been demonstrated in endothelial cells that constitutively express eNOS (12, 13) and provides a convenient method to assay the effect of endogenously produced NO⅐ on respiration.
Sham and Band myocytes were incubated in the O 2 electrode chamber (1 ml volume ϭ 240 nmol O 2 ), and O 2 consumption was monitored continuously down to the baseline. Figure 3A shows typical respiration profiles for Sham and Band myocytes, indicating that the respiration of Band but not Sham myocytes becomes progressively slower as O 2 tension falls (solid lines). Consistent with this effect being due to endogenously produced NO⅐, the nonspecific NOS inhibitor nitro-Larginine (1 mM) eliminated the deceleration of O 2 consumption rate, resulting in a respiration profile that was almost linear down to the baseline (dotted lines). Nitro-L-arginine had no effect on Sham myocyte respiration. The selective iNOS inhibitor 1400W (400 M) also gave identical results to those seen with nitro-L-arginine (Fig. 3B) indicating that the principal source of NO⅐ in these myocytes is iNOS. This is consistent with iNOS immunoblot and activity results shown in Fig. 2 and Table 1 . Figure 4 shows a quantitative representation of several experiments of the type in Fig. 3 in which respiration rates were calculated at various time points and expressed as a percentage of the maximum rate as a function of O 2 tension. This linear-fit analysis of the data indicates significant differences in the respiration profiles of Sham (Fig. 4A) and Band (Fig. 4B ) cardiomyocytes (filled symbols) that are normalized by nitro-L-arginine (open symbols). It is interesting to note that the respiration rate of Band myocytes is sensitive to the NOS inhibitor across a wide range of O 2 tensions, up to ϳ200 M. This suggests that the effects of NO⅐ on respiration may not only be important at low but also at high O 2 tensions.
In further support of a bioenergetic defect at the mitochondrial level in cardiac hypertrophy, the steady- Reactions were performed without Ca 2ϩ to measure iNOS activity or with 0.6 mM CaCl2 to measure total NOS activity. * P Ͻ 0.05 between sham and Band groups. 
Effects of endogenous NO⅐ on contractile function in hypertrophy.
Because the experiments in isolated myocytes were performed in the presence of a mitochondrial uncoupler, the possibility remains that the effects of NO⅐ on mitochondrial respiration may be unique to the uncoupled system. Therefore, in the next series of experiments, a NOS inhibitor was used to assess the effects of endogenously generated NO⅐ on mitochondrial function in the intact working heart. We examined the contractile function of Sham and Band hearts, specifically their ability to respond to a pacing workload directly related to mitochondrial ATP-generating capacity. Hearts were paced from 300 to 480 beats/min, allowed to recover, and then perfused with 1 mM nitro-L-arginine and paced again. As the data in Fig. 5 show, pacing resulted in a progressive decline in LV developed pressure, which was more pronounced in Band than Sham hearts but not significantly different. Most strikingly, the NOS inhibitor resulted in a significant improvement in cardiac function in Band hearts. No such improvement was seen in Sham hearts with the NOS inhibitor eliciting a slightly poorer response to pacing and ruling out a contribution from eNOS in this perfusion system. These results are consistent with the hypothesis that endogenously generated NO⅐ is able to regulate mitochondrial ATP generation at the intact organ level, and that in the hypertrophied heart, this has a direct impact on cardiac function.
The addition of nitro-L-arginine elicited similar increases in coronary vascular resistance in both groups (not shown). This result indicates that in this system, the NOS inhibitor can enter endothelial cells and inhibit eNOS, and thus by inference can enter myocytes and inhibit iNOS. It is interesting to note that at the highest pacing point (480 beats/min), the NOS inhibitor was unable to significantly improve the function of Band hearts. This is possibly due to other factors that limit LV function at high heart rate but are not NO⅐ sensitive. In contrast to the NOS inhibitor, the NOS substrate arginine (1 mM) had no effect on cardiac function in either Sham or Band hearts (results not shown), suggesting no substrate limitation for NO⅐ production.
DISCUSSION
The principal findings of this study are as follows: 1) myocytes from hypertrophied hearts exhibit elevated iNOS protein and activity; 2) respiration of hypertrophied myocytes is more sensitive to NO⅐; and 3) endogenously produced NO⅐ can inhibit mitochondrial respiration both in intact cells and at the whole organ level.
In a previous study (8) , we determined that mitochondria isolated from hypertrophied hearts are more sensitive to inhibition of cytochrome c oxidase. Because NO⅐ is a physiological inhibitor of this enzyme (9) (10) (11) , and iNOS is upregulated in hypertrophied hearts (8) , it was hypothesized that the combination of more NO⅐ and a greater sensitivity to it may result in a bioenergetic defect at the tissue level. However, the possibility remained that this phenomenon was unique to isolated mitochondria and may have been due to the mitochondrial isolation procedure itself. In addition, these previous experiments were performed at saturating O 2 tensions (ϳ240 M) i.e., far higher than those experienced at the cell level. In the current investigation, myocytes were isolated from hypertrophied and control hearts and various NO⅐ and mitochondrial parameters were studied to determine whether NO⅐ can regulate mitochondrial respiration at the intact cell level in hypertrophy. In addition, intact perfused hearts were studied to test this hypothesis at the whole organ level.
The most important finding in our study was that endogenously formed NO⅐ was increased and could inhibit hypertrophied myocyte respiration. When NO⅐ synthesis was blocked by both nonspecific (nitro-L-arginine) and specific (1400W) iNOS inhibitors (Figs. 3  and 4) , O 2 consumption in Band myocytes was restored to the level seen in Sham myocytes, suggesting that endogenous NO⅐ from iNOS has an important physiological role in the control of myocyte O 2 consumption in hypertrophy.
The effects of NOS inhibitors on cell respiration (Figs. 3 and 4) are similar to those seen in endothelial cells (12) that constitutively express eNOS. It has been proposed that eNOS can modulate respiration in myocytes and whole tissues (6, 25, 26, 28, 39, 49, 50) . However, the observation that 1400W (18) has the same effect as nitro-L-arginine suggests iNOS is the sole source of NO⅐ in hypertrophied myocytes. Nevertheless, by using Western blotting, we determined which isoforms of NOS were expressed in myocytes. This method revealed an upregulation in iNOS in Band myocytes ( Fig. 2A) , in agreement with our previous findings in whole heart homogenates (8) . NOS activity results also showed enhanced iNOS activity in Band myocytes, demonstrating that the upregulated iNOS protein was enzymatically active.
The conventional view of iNOS is as a pathological NOS induced by cytokines such as interleukin-1␤, interferon-␥, and tumor necrosis factor-␣ (16, 30, 45) . However, more recently, low-level constitutive expression of iNOS has been demonstrated in several tissues including the kidney, heart, and blood vessels under normal conditions (30, 32) . Our previous report (8) and our current findings show that low-level iNOS is expressed in control heart tissue and myocytes and is elevated in the hypertrophied heart. Interestingly, the observation that fetal isozymes are over expressed in hypertrophy (48) is corroborated by recent findings that iNOS is abundantly expressed in the fetus (7), suggesting common gene regulatory pathways.
It is striking that the difference in the effect of NOS inhibitors on the respiration of Band and Sham myocytes is far greater than would be predicted from the difference in iNOS level and activity. However, it must be noted that the effect of NO⅐ on respiration is the result of not only iNOS activity, but also the sensitivity of respiration to NO⅐. Previously, we observed that isolated mitochondria from Band hearts exhibit greater sensitivity to NO⅐ (8) . The results in Fig. 1 demonstrate that this phenomenon is maintained at the myocyte level, i.e., mitochondria within hypertrophied myocytes are more sensitive to NO⅐ inhibition. The result of this increased sensitivity is that a small change in the level of endogenously produced NO⅐, such as would be experienced with iNOS up-regulation in hypertrophy, can have large effects on respiration rate.
Importantly, it appears that the effects of endogenously generated NO⅐ observed in intact myocytes can be recapitulated at the intact organ level, as exemplified by the experiments shown in Fig. 5 . These results are consistent with an effect of NO⅐ on mitochondrial respiration, as measured previously in isolated mitochondria and here in myocytes. There is still considerable debate as to whether NO⅐ is a physiological inhibitor of mitochondrial respiration. Addition of exogenous NO⅐ to cells certainly inhibits respiration, although the concentrations required are relatively high (IC 50 ϳ250 nM in the current investigation), possibly due to the high O 2 tensions in these experiments. Even when the effects of endogenous NO⅐ are examined, stimulation of the NO⅐ producing machinery (e.g., iNOS with cytokines, eNOS with bradykinin) is usually required (13, 45) . This study is among the first to show an effect of baseline levels of NO⅐ on cellular respiration, i.e., without NOS stimulation. To reveal this effect, low O 2 tensions were required, as shown in Figs. 3 and 4 . Although these results were obtained in a pathological condition, cardiac hypertrophy, they have implications for the interaction between NO⅐ and mitochondria under physiological conditions, where low fluxes of NO⅐ may be continuously generated.
The precise role of NO⅐ in cardiac hypertrophy is also controversial. It has been reported that endothelial NO⅐ generation is elevated during the initial phases of pacing induced cardiac hypertrophy (31) but that NO⅐ production is lowered during the decompensation phase of pacing induced heart failure (36) . The initial elevation in NO⅐ may be a compensatory mechanism to elevate coronary blood flow, due to the increased metabolic demand on the heart caused by greater workload. Indeed, Heymes et al. (20) suggest that elevated iNOS and eNOS in dilated cardiomyopathy may have beneficial effects on LV diastolic function by enhancing preload reserve. This may be accompanied by an NO⅐-induced lowering of the inotropic response to ␤ 1 -adrenergic stimulation (16, 45) .
These results are consistent with our previous study, suggesting that NO⅐-mediated mitochondrial dysfunction is only apparent under conditions of stress (8) . As hypertrophy progresses, the initial benefits of elevated NO⅐ may be lost, and NO⅐ may then contribute to the pathology of hypertrophy when its preservation of mitochondrial function begins to interfere with ATP synthesis. Indeed, as end-stage heart failure develops, a pathological role for NO⅐ appears to prevail (16, 21, 31, 46) . The results presented are consistent with the hypothesis that during the stable, nonfailing phase of cardiac hypertrophy, NO⅐ has a pathological role targeted at the level of mitochondrial respiration and ATP synthesis. This is, then, expected to directly impact on contractile function under stress, as suggested by the data from working hearts (Fig. 5) . Overall, it appears that mitochondria in hypertrophy are subject to a double insult, in that they are both more sensitive to NO⅐ and exposed to more of it. Such an insult may contribute to certain pathologies of cardiac hypertrophy.
